literature

HIV mutation literature information.

Rilpivirine: a new non-nucleoside reverse transcriptase inhibitor.

PMID: 23099850 2013 The Journal of antimicrobial chemotherapy

Abstract: Seventeen NNRTI mutations have been associated with decreased susceptibility to rilpivirine: K101E/P, E138A/G/K/Q/R, V179L, Y181C/I/V, H221Y, F227C, M230I/L, Y188L and the combination L100I + K103N.

Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.

PMID: 22842995 2013 AIDS (London, England)

Abstract: The prevalence of RPV RAMs was K101E (9.1%), K101P (1.4%), E138A (3.9%), E138G (0.3%), E138K (0.3%), E138Q (0.8%), V179L (0.2%), Y181C (21.8%), Y181I (0.5%), Y181V (0.2%), H221Y (8.3%), F227C (0.1%) and M230L (1.5%).

Emerging mutations and associated factors in patients displaying treatment failure on an etravirine-containing regimen.

PMID: 22267476 2012 Antiviral therapy

Abstract: NNRTI mutations selected were V179I (5 patients), V179L (1), V179F (2), L100I (1), K103N (2), Y181C (3), K101E (1), K101R (1) and H221Y (1).

Browser Board

Co-occurred Entities

Filtrator